文献速递甲状腺核医学

FDG-PET/CT在不确定性甲状腺结节中的应用:一项随机对照试验的成本-效用分析

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-18

该研究基于一项随机对照多中心试验,评估[18F]FDG-PET/CT驱动的诊断方案对比诊断性手术,用于Bethesda III/IV细胞学甲状腺结节的成本效果。132例患者参与,[18F]FDG-PET/CT避免了40%对良性Bethesda III/IV结节的无效诊断性手术。 lifelong社会成本和QALYs通过Markov模型外推,在支付意愿€50,000/QALY下,[18F]FDG-PET/CT驱动方案具有成本效果的概率为84%。

要点

  • [18F]FDG-PET/CT避免40%对良性Bethesda III/IV结节的无效诊断性手术。
  • 1年甲状腺结节相关成本差异为-€1000(95%CI:-€2100至€0,p=0.06)。
  • 支付意愿€50,000/QALY时,[18F]FDG-PET/CT驱动方案具有成本效果的概率为84%。

核心结论

  • 在观察到诊断性手术减少后,[18F]FDG-PET/CT驱动的诊断方案降低了1年甲状腺结节相关成本和社会成本,同时维持了生活质量。
  • 对于Bethesda III/IV结节,[18F]FDG-PET/CT驱动方案对比诊断性手术很可能具有成本效果。

研究设计与样本

  • 研究纳入132例参与随机对照多中心试验的患者,比较[18F]FDG-PET/CT与诊断性手术。
  • 观察到的1年试验结果使用Markov模型外推,评估终身社会成本和QALYs。
  • 使用成本效果可接受曲线估计成本效果概率,考虑抽样、插补和参数的不确定性。
  • 试验注册号:ClinicalTrials.gov NCT02208544(2014年8月5日)。

主要发现

  • 观察到的1年甲状腺结节相关成本差异为-€1000(95%CI:-€2100至€0,p=0.06)。
  • 从更广泛的社会视角,1年总社会成本差异为-€4500(95%CI:-€9200至€150,p=0.06)。
  • 在模型终身期间,成本差异为-€9900(95%CI:-€23,100至€3200,p=0.14)。
  • QALYs差异在1年时为0.019(95%CI:-0.045至0.083,p=0.57),终身期间为0.402(95%CI:-0.581至1.385,p=0.42)。
  • 在支付意愿€50,000/QALY下,[18F]FDG-PET/CT驱动方案是具有成本效果的策略,确定性为84%。

关键数值与推荐

  • [18F]FDG-PET/CT避免了40%对良性Bethesda III/IV结节的无效诊断性手术。
  • 1年甲状腺结节相关成本差异为-€1000(95%CI:-€2100至€0,p=0.06)。
  • 1年总社会成本差异为-€4500(95%CI:-€9200至€150,p=0.06)。
  • 终身成本差异为-€9900(95%CI:-€23,100至€3200,p=0.14)。
  • 支付意愿€50,000/QALY时,[18F]FDG-PET/CT驱动方案具有成本效果的概率为84%。

临床怎么用

  • 对于Bethesda III/IV细胞学甲状腺结节,[18F]FDG-PET/CT驱动的诊断方案对比诊断性手术很可能具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate cost-effectiveness of an [18F]FDG-PET/CT-driven diagnostic workup as compared to diagnostic surgery, for thyroid nodules with Bethesda III/IV cytology. [18F]FDG-PET/CT avoids 40% of futile diagnostic surgeries for benign Bethesda III/IV nodules. METHODS: Lifelong societal costs and quality-adjusted life years (QALYs) were assessed for 132 patients participating in a randomised controlled multicentre trial comparing [18F]FDG-PET/CT to diagnostic surgery. The observed 1-year trial results were extrapolated using a Markov model. The probability of cost-effectiveness was estimated using cost-effectiveness acceptability curves, taking uncertainty about sampling, imputation, and parameters into account. RESULTS: The observed 1-year cost difference of [18F]FDG-PET/CT as compared to diagnostic surgery was - €1000 (95% CI: - €2100 to €0) for thyroid nodule-related care (p = 0.06). From the broader societal perspective, the 1-year difference in total societal costs was - €4500 (- €9200 to €150) (p = 0.06). Over the modelled lifelong period, the cost difference was - €9900 (- €23,100 to €3200) (p = 0.14). The difference in QALYs was 0.019 (- 0.045 to 0.083) at 1 year (p = 0.57) and 0.402 (- 0.581 to 1.385) over the lifelong period (p = 0.42). For a willingness to pay of €50,000 per QALY, an [18F]FDG-PET/CT-driven work-up was the cost-effective strategy with 84% certainty. CONCLUSION: Following the observed reduction in diagnostic surgery, an [18F]FDG-PET/CT-driven diagnostic workup reduced the 1-year thyroid nodule-related and societal costs while sustaining quality of life. It is very likely cost-effective as compared to diagnostic surgery for Bethesda III/IV nodules. TRIAL REGISTRATION NUMBER: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. de Koster EJ, Vriens D, van Aken MO, et al. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. Eur J Nucl Med Mol Imaging. 2022. PMID: 35435497. doi:10.1007/s00259-022-05794-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。